INHBE

Summary

INHBE (inhibin subunit beta E, HGNC:24029) is a protein-coding gene on chromosome 12q13.3, encoding Inhibin beta E chain (P58166). Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland.

This gene encodes a member of the TGF-beta (transforming growth factor-beta) superfamily of proteins. The encoded preproprotein is proteolytically processed to generate an inhibin beta subunit. Inhibins have been implicated in regulating numerous cellular processes including cell proliferation, apoptosis, immune response and hormone secretion. This gene may be upregulated under conditions of endoplasmic reticulum stress, and this protein may inhibit cellular proliferation and growth in pancreas and liver.

Source: NCBI Gene 83729 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 52 total
• MANE Select transcript: NM_031479

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24029
Approved symbol	INHBE
Name	inhibin subunit beta E
Location	12q13.3
Locus type	gene with protein product
Status	Approved
Aliases	activin, MGC4638
Ensembl gene	ENSG00000139269
Ensembl biotype	protein_coding
OMIM	612031
Entrez	83729

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 3 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000266646, ENST00000547970, ENST00000551553, ENST00000553033, ENST00000898806, ENST00000898807

RefSeq mRNA: 1 — MANE Select: NM_031479 NM_031479

CCDS: CCDS8939

Canonical transcript exons

ENST00000266646 — 2 exons

Exon	Start	End
ENSE00000937306	57455307	57455834
ENSE00001278408	57456094	57458025

Expression profiles

Bgee: expression breadth ubiquitous, 108 present calls, max score 95.33.

FANTOM5 (CAGE): breadth broad, TPM avg 5.7222 / max 575.2982, expressed in 691 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
126211	4.2397	605
126214	0.5194	159
126208	0.3251	94
126212	0.2457	97
126213	0.2352	89
126209	0.1107	33
126210	0.0464	23

Top tissues by expression

261 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	95.33	gold quality
liver	UBERON:0002107	94.02	gold quality
stromal cell of endometrium	CL:0002255	72.51	gold quality
gastrocnemius	UBERON:0001388	61.69	gold quality
hindlimb stylopod muscle	UBERON:0004252	61.68	gold quality
muscle of leg	UBERON:0001383	61.49	gold quality
muscle organ	UBERON:0001630	58.53	gold quality
islet of Langerhans	UBERON:0000006	55.61	gold quality
cerebellar cortex	UBERON:0002129	54.06	gold quality
cerebellar hemisphere	UBERON:0002245	53.93	gold quality
cerebellum	UBERON:0002037	53.16	gold quality
right hemisphere of cerebellum	UBERON:0014890	53.01	gold quality
skeletal muscle tissue	UBERON:0001134	52.28	gold quality
muscle tissue	UBERON:0002385	52.02	gold quality
bone marrow cell	CL:0002092	51.60	gold quality
pituitary gland	UBERON:0000007	50.21	gold quality
Brodmann (1909) area 46	UBERON:0006483	49.30	gold quality
blood vessel layer	UBERON:0004797	49.29	gold quality
quadriceps femoris	UBERON:0001377	49.25	gold quality
adenohypophysis	UBERON:0002196	49.20	gold quality
cervix squamous epithelium	UBERON:0006922	49.20	gold quality
hair follicle	UBERON:0002073	49.18	gold quality
cortex of kidney	UBERON:0001225	49.04	gold quality
olfactory bulb	UBERON:0002264	48.92	gold quality
choroid plexus epithelium	UBERON:0003911	48.89	gold quality
myocardium	UBERON:0002349	48.87	gold quality
type B pancreatic cell	CL:0000169	48.83	gold quality
buccal mucosa cell	CL:0002336	48.67	gold quality
vastus lateralis	UBERON:0001379	48.67	gold quality
metanephros	UBERON:0000081	48.61	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ATF4, ZNF804A

miRNA regulators (miRDB)

30 targeting INHBE, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-580-3P	99.67	69.23	1841
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-4797-5P	99.39	68.01	1354
HSA-MIR-4667-3P	99.26	65.45	1608
HSA-MIR-6734-3P	99.15	66.27	1627
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-4477A	98.83	69.75	2952
HSA-MIR-5006-5P	98.79	66.92	1246
HSA-MIR-619-3P	98.38	65.58	693
HSA-MIR-4436B-3P	98.25	65.26	1494
HSA-MIR-6735-5P	98.24	65.36	1488
HSA-MIR-7843-5P	98.12	65.26	1421
HSA-MIR-4469	97.93	65.81	1319
HSA-MIR-1279	97.83	67.50	1898
HSA-MIR-4632-5P	97.82	65.38	1470
HSA-MIR-6879-5P	97.77	65.52	1521
HSA-MIR-6748-3P	97.20	65.66	836
HSA-MIR-6747-5P	96.17	64.99	743
HSA-MIR-6846-3P	94.80	65.19	389
HSA-MIR-371B-3P	94.48	66.59	345

Literature-anchored findings (GeneRIF, showing 12)

• cDNA cloning from a liver cDNA library, deduction of amino acid sequence, binding to follistatin, and analysis of the transcript in human liver (PMID:12242034)
• activin E has a role in regulating the proliferation of pancreatic exocrine cells (PMID:16426570)
• Expression of the inhibin betaC and betaE subunits was demonstrated at the protein level and at the transcriptional level in normal human endometrial tissue and in the Ishikawa human endometrial carcinoma cell line. (PMID:20012305)
• An immunolabelling of the inhibin-betaE subunit in normal and malignant cervical tissue, as well as cervical cancer cells, is demonstrated. (PMID:20033758)
• differential expression pattern of the betaC- and betaE-subunits in normal human endometrial tissue suggests that they function in endometrial maturation and blastocyst implantation. (PMID:21092084)
• The inhibin-betaC subunit is down-regulated, while inhibin-betaE is up-regulated by interferon-beta1a in Ishikawa carcinoma cell line. (PMID:23580013)
• Activin A, B, and AB have similar effects on steroidogenesis in human granulosa cells; in contrast, activin AC is not biologically active and does not act as a competitive antagonist. (PMID:25062451)
• INHBE functions as a possible hepatokine to alter the whole-body metabolic status under obese insulin-resistant condition (PMID:29596463)
• The Significance of INHBE Expression in the Cancer Cells of Clear-Cell Renal Cell Carcinoma. (PMID:34515260)
• Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity. (PMID:35896531)
• Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. (PMID:35999217)
• Identification and validation of INHBE and P4HA1 as hub genes in non-alcoholic fatty liver disease. (PMID:37922570)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Inhbe	ENSMUSG00000047492
rattus_norvegicus	Inhbe	ENSRNOG00000007601

Paralogs (31): TGFB2 (ENSG00000092969), BMP7 (ENSG00000101144), TGFB1 (ENSG00000105329), BMP5 (ENSG00000112175), BMP8B (ENSG00000116985), TGFB3 (ENSG00000119699), INHBA (ENSG00000122641), INHA (ENSG00000123999), BMP4 (ENSG00000125378), BMP2 (ENSG00000125845), GDF5 (ENSG00000125965), GDF1 (ENSG00000130283), BMP15 (ENSG00000130385), GDF15 (ENSG00000130513), GDF11 (ENSG00000135414), MSTN (ENSG00000138379), LEFTY2 (ENSG00000143768), GDF7 (ENSG00000143869), BMP3 (ENSG00000152785), BMP6 (ENSG00000153162), GDF6 (ENSG00000156466), NODAL (ENSG00000156574), INHBB (ENSG00000163083), BMP10 (ENSG00000163217), GDF9 (ENSG00000164404), INHBC (ENSG00000175189), BMP8A (ENSG00000183682), GDF3 (ENSG00000184344), LEFTY1 (ENSG00000243709), GDF2 (ENSG00000263761), GDF10 (ENSG00000266524)

Protein

Protein identifiers

Inhibin beta E chain — P58166 (reviewed: P58166)

Alternative names: Activin beta-E chain

All UniProt accessions (1): P58166

UniProt curated annotations — full annotation on UniProt →

Function. Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins. Activin E is a homodimer of INHBE secreted by the liver that plays a crucial role in regulating metabolic homeostasis particularly in lipid metabolism and energy homeostasis. Plays a central role in the regulation of adipose tissue lipolysis by preventing the influx of fatty acids from adipose tissue into the liver. Mechanistically, signals via ACVR1C to activate SMAD2/3 signaling, suppressing PPARG target genes in adipose tissue, thereby reducing liver lipid content and improving glycemic control. Induces beige adipocyte formation and thermogenesis in response to cold exposure.

Subunit / interactions. Homodimeric or heterodimeric through association with alpha and beta subunits, linked by one or more disulfide bonds. Inhibins are heterodimers of one alpha and one beta subunit. Activins are homo- or heterodimers of beta subunits only.

Subcellular location. Secreted.

Similarity. Belongs to the TGF-beta family.

RefSeq proteins (1): NP_113667* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001318	Inhibin_betaC	Family
IPR001839	TGF-b_C	Domain
IPR015615	TGF-beta-like	Family
IPR017948	TGFb_CS	Conserved_site
IPR029034	Cystine-knot_cytokine	Homologous_superfamily

Pfam: PF00019

UniProt features (11 total): disulfide bond 5, sequence variant 2, signal peptide 1, propeptide 1, chain 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P58166-F1	75.32	0.22

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (5): 240–248, 247–315, 276–347, 280–349, 314

Glycosylation sites (1): 198

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-209822	Glycoprotein hormones
R-HSA-209952	Peptide hormone biosynthesis
R-HSA-2980736	Peptide hormone metabolism
R-HSA-392499	Metabolism of proteins

MSigDB gene sets: 109 (showing top): RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GOMF_GROWTH_FACTOR_ACTIVITY, TAL1ALPHAE47_01, GGGTGGRR_PAX4_03, ZHAN_MULTIPLE_MYELOMA_CD1_UP, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, GATA1_01, GOMF_CYTOKINE_ACTIVITY, GOBP_NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS, NOJIMA_SFRP2_TARGETS_UP, GOBP_CONNECTIVE_TISSUE_DEVELOPMENT, HAN_SATB1_TARGETS_DN, GOMF_SIGNALING_RECEPTOR_BINDING

GO Biological Process (3): cell surface receptor protein serine/threonine kinase signaling pathway (GO:0007178), negative regulation of adipose tissue development (GO:1904178), activin receptor signaling pathway (GO:0032924)

GO Molecular Function (3): cytokine activity (GO:0005125), hormone activity (GO:0005179), growth factor activity (GO:0008083)

GO Cellular Component (3): obsolete extracellular space (GO:0005615), extracellular matrix (GO:0031012), extracellular region (GO:0005576)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Peptide hormone biosynthesis	1
Peptide hormone metabolism	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
receptor ligand activity	3
enzyme-linked receptor protein signaling pathway	1
negative regulation of developmental process	1
negative regulation of multicellular organismal process	1
adipose tissue development	1
regulation of adipose tissue development	1
transforming growth factor beta receptor superfamily signaling pathway	1
external encapsulating structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

832 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
INHBE	VLDLR	P98155	739
INHBE	FST	P19883	585
INHBE	LRP8	Q14114	557
INHBE	YWHAQ	P27348	542
INHBE	ACVR1C	Q8NER5	495
INHBE	FZD4	Q9ULV1	425
INHBE	RELN	P78509	424
INHBE	CACNG8	Q8WXS5	417
INHBE	MIOX	Q9UGB7	398
INHBE	CHAC1	Q9BUX1	393
INHBE	WDR70	Q9NW82	388
INHBE	PTCH1	Q13635	387
INHBE	PTCH2	Q9Y6C5	373
INHBE	TBP	P20226	369
INHBE	AMHR2	Q16671	363

IntAct

38 interactions, top by confidence:

A	B	Type	Score
C1QTNF9	C1QTNF9B	psi-mi:“MI:0914”(association)	0.780
UST	GOLIM4	psi-mi:“MI:0914”(association)	0.530
DKK3	NME4	psi-mi:“MI:0914”(association)	0.530
	PLOD2	psi-mi:“MI:0914”(association)	0.530
C1QTNF9B	PLOD3	psi-mi:“MI:0914”(association)	0.530
INHBE	HSPA5	psi-mi:“MI:0914”(association)	0.530
NOTCH2	ZNF316	psi-mi:“MI:0914”(association)	0.530
APP	ZNF724	psi-mi:“MI:0914”(association)	0.350
CPA2	NME4	psi-mi:“MI:0914”(association)	0.350
INHBE	MYO1F	psi-mi:“MI:0914”(association)	0.350
COLEC10	PTX3	psi-mi:“MI:0914”(association)	0.350
PDGFRA	GXYLT2	psi-mi:“MI:0914”(association)	0.350
NOTCH2	ZNF320	psi-mi:“MI:0914”(association)	0.350
LLCFC1	POTEF	psi-mi:“MI:0914”(association)	0.350
CCL3	KRBA1	psi-mi:“MI:0914”(association)	0.350
ST14	LIPT2	psi-mi:“MI:0914”(association)	0.350
SCGB2A2	RTL8C	psi-mi:“MI:0914”(association)	0.350
PCDHGB5	FAM171A2	psi-mi:“MI:0914”(association)	0.350
SCAP	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
DKK3	MYO9A	psi-mi:“MI:0914”(association)	0.350
FAM234A	IFRD1	psi-mi:“MI:0914”(association)	0.350
C1orf54	AGRN	psi-mi:“MI:0914”(association)	0.350
COLEC10	PLOD2	psi-mi:“MI:0914”(association)	0.350
TMPRSS13	TOR1A	psi-mi:“MI:0914”(association)	0.350
HPN	TOR1A	psi-mi:“MI:0914”(association)	0.350
LY6H	NXPH4	psi-mi:“MI:0914”(association)	0.350
WFDC6	HSPA5	psi-mi:“MI:0914”(association)	0.350

BioGRID (55): INHBE (Affinity Capture-RNA), INHBE (Affinity Capture-MS), INHBE (Affinity Capture-MS), INHBE (Affinity Capture-MS), INHBE (Affinity Capture-MS), INHBE (Affinity Capture-MS), VHL (Affinity Capture-MS), FAM169A (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), MYO1F (Affinity Capture-MS), PRMT7 (Affinity Capture-MS), INHBE (Affinity Capture-MS), ANKRD46 (Affinity Capture-MS), INHBE (Affinity Capture-MS), INHBE (Affinity Capture-MS)

ESM2 similar proteins: A5PJ93, E9PY61, H2N4I1, O00391, O08717, P01180, P01183, P08833, P21743, P24591, P43031, P47876, P51693, P55103, P58166, Q03157, Q15904, Q28686, Q561R0, Q58CS8, Q5Q0T9, Q5RJL6, Q6AZ60, Q6IUU3, Q6PRD1, Q6Q484, Q6S5C2, Q75ZP3, Q80WF4, Q80YF6, Q864V4, Q8BND5, Q8C1Q4, Q8CAL5, Q8CEF9, Q8CG70, Q8CJ26, Q8IVL6, Q8JGM4, Q8K5A9

Diamond homologs: A8E7N9, G5EEL5, O08717, O18828, O18830, O19006, O42222, O46564, O46576, O88959, O95390, O95393, O95972, P03970, P07713, P07995, P08476, P09534, P12643, P12644, P12645, P18075, P18331, P20722, P20863, P21274, P21275, P22003, P22004, P22444, P23359, P25703, P27092, P27539, P30884, P30885, P30886, P34820, P34821, P34822

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ZNF804A	“up-regulates quantity by expression”	INHBE	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

52 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	47
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

162 predictions. Top by Δscore:

Variant	Effect	Δscore
12:57456088:G:A	acceptor_gain	1.0000
12:57455781:G:GT	donor_gain	0.9900
12:57456087:C:CA	acceptor_gain	0.9900
12:57456092:A:AG	acceptor_gain	0.9900
12:57456093:G:GG	acceptor_gain	0.9900
12:57456080:T:A	acceptor_gain	0.9800
12:57456090:GCAG:G	acceptor_loss	0.9800
12:57456092:AGACT:A	acceptor_loss	0.9800
12:57455807:G:GT	donor_gain	0.9700
12:57456093:GACT:G	acceptor_gain	0.9700
12:57455831:ACAG:A	donor_loss	0.9600
12:57455832:CAGG:C	donor_loss	0.9600
12:57455833:AGGT:A	donor_loss	0.9600
12:57455834:GGT:G	donor_loss	0.9600
12:57455835:G:GA	donor_loss	0.9600
12:57455836:T:A	donor_loss	0.9600
12:57456093:GA:G	acceptor_gain	0.9600
12:57456093:GAC:G	acceptor_gain	0.9600
12:57456093:GACTC:G	acceptor_gain	0.9600
12:57455797:G:T	donor_gain	0.9500
12:57456080:T:TA	acceptor_loss	0.9500
12:57455833:AGGTG:A	donor_gain	0.9300
12:57456088:GGGCA:G	acceptor_gain	0.9200
12:57456089:GGCAG:G	acceptor_gain	0.9200
12:57456090:GCAGA:G	acceptor_gain	0.9200
12:57456091:CA:C	acceptor_gain	0.9200
12:57456092:A:T	acceptor_gain	0.9200
12:57456093:G:T	acceptor_gain	0.9100
12:57455782:G:T	donor_gain	0.8900
12:57455781:G:T	donor_gain	0.8800

AlphaMissense

2222 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:57456562:T:G	F256C	0.998
12:57456578:G:C	W261C	0.997
12:57456578:G:T	W261C	0.997
12:57456587:G:C	W264C	0.997
12:57456587:G:T	W264C	0.997
12:57456576:T:A	W261R	0.992
12:57456576:T:C	W261R	0.992
12:57456589:T:C	I265T	0.992
12:57456621:T:A	C276S	0.992
12:57456622:G:C	C276S	0.992
12:57456623:C:G	C276W	0.992
12:57456633:T:A	C280S	0.992
12:57456634:G:C	C280S	0.992
12:57456561:T:C	F256L	0.991
12:57456563:C:A	F256L	0.991
12:57456563:C:G	F256L	0.991
12:57456622:G:A	C276Y	0.991
12:57456562:T:C	F256S	0.990
12:57456585:T:A	W264R	0.989
12:57456585:T:C	W264R	0.989
12:57456633:T:C	C280R	0.989
12:57456739:G:A	C315Y	0.989
12:57456835:G:A	C347Y	0.989
12:57456738:T:A	C315S	0.988
12:57456739:G:C	C315S	0.988
12:57456774:T:G	Y327D	0.988
12:57456840:T:A	C349S	0.987
12:57456841:G:C	C349S	0.987
12:57456606:T:G	Y271D	0.986
12:57456622:G:T	C276F	0.985

dbSNP variants (sampled 300 via entrez): RS1001654958 (12:57455059 G>A), RS1002404220 (12:57455676 C>G), RS1003400802 (12:57454220 C>G), RS1003610832 (12:57457905 A>G), RS1003640385 (12:57454626 C>T), RS1004901898 (12:57455099 GC>G), RS1005362844 (12:57455607 C>A), RS1005381126 (12:57456869 G>A), RS1005605852 (12:57454157 C>T), RS1005647635 (12:57456736 G>A), RS1005659710 (12:57453920 A>G), RS1005987312 (12:57455299 C>A,T), RS1006868105 (12:57453462 G>A), RS1007107036 (12:57453728 T>C), RS1007451921 (12:57454893 C>T)

Disease associations

OMIM: gene MIM:612031 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST001791_11	Urate levels	2.000000e-25
GCST004603_110	Platelet count	3.000000e-11
GCST004862_96	Itch intensity from mosquito bite adjusted by bite size	6.000000e-06
GCST006611_116	HDL cholesterol	7.000000e-11
GCST90002400_718	Plateletcrit	5.000000e-13
GCST90002402_134	Platelet count	1.000000e-19
GCST90002404_139	Red cell distribution width	3.000000e-12

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0004531	urate measurement
EFO:0004309	platelet count
EFO:0008377	mosquito bite reaction itch intensity measurement
EFO:0008378	mosquito bite reaction size measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0007985	platelet crit
EFO:0009188	Red cell distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

125 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cyclosporine	affects expression, decreases expression, increases expression	7
Benzo(a)pyrene	decreases expression, increases methylation	5
Aflatoxin B1	affects expression, decreases expression	5
sodium arsenite	increases expression, decreases expression	4
Amiodarone	increases expression	4
Estradiol	affects cotreatment, decreases expression, increases reaction, increases expression	4
Tunicamycin	increases expression	4
Valproic Acid	increases expression, affects expression, decreases expression	4
Amitriptyline	increases expression	3
Fluoxetine	increases expression	3
Ketoconazole	increases expression	3
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression	3
bisphenol A	affects expression, increases expression	2
perfluorooctanoic acid	increases expression	2
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, increases expression	2
mercuric bromide	increases expression, affects cotreatment	2
azoxystrobin	decreases expression	2
entinostat	increases expression, affects cotreatment	2
bisphenol S	decreases expression	2
Panobinostat	affects cotreatment, increases expression	2
Acetaminophen	decreases expression, increases expression	2
Chlorpromazine	increases expression	2
Clomipramine	increases expression	2
Clozapine	increases expression	2
Drugs, Chinese Herbal	increases expression	2
Flecainide	increases expression	2
Imipramine	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tamoxifen	increases expression	2
Thioridazine	increases expression	2

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7SA	Ubigene A-549 INHBE KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.